Clinical Research Directory
Browse clinical research sites, groups, and studies.
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
Sponsor: Anhui Provincial Hospital
Summary
The objective of this real world study is to confirm the efficacy and saftey of Telpegfilgrastim injection for the prevention of chemotherapy-induced Neutropenia in Patients With Malignant solid tumor.
Official title: A Real World Study on the Efficacy and Safety of Telpegfilgrastim Injection for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Solid Tumor
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
OBSERVATIONAL
Enrollment
318
Start Date
2024-08-15
Completion Date
2025-08-15
Last Updated
2025-07-31
Healthy Volunteers
Not specified
Conditions
Interventions
Telpegfilgrastim Injection
Within 48 ± 12 hours after the end of each chemotherapy cycle, a single subcutaneous injection of a fixed dose of 2mg of Telpegfilgrastim is administered. Use once per chemotherapy cycle and enroll in 1-4 cycles based on the patient's actual condition.
Locations (2)
Anhui province hospital
Hefei, Anhui, China
Anhui province hospital
Hefei, Anhui, China